Dr. Jonathan T. Jacobs, M.D.
Internal Medicine (Internal Medicine Physician)
Medicare and federal program status
Opted out of Medicare from July 9, 2017 through July 9, 2027. Medicare does not pay for this clinician’s services: patients with Medicare sign a private contract and pay the clinician directly. They can still order tests and refer Medicare patients to other providers.
Source: CMS Medicare Opt Out Affidavits (record last updated August 15, 2025). Opting out is a legal choice many clinicians make, often to run a cash or concierge practice.
At a glance
- In the NPI registry since
- 2006
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Internal Medicine Physician primary
KS license 0429916 · KS license 04-29916 · MO license 2002028986 -
Hospitalist Physician
KS license 0429916 · MO license 2002028986 -
Pediatrics Physician
KS license 04-29916 · MO license 2002028986
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 12 companies reported 24 payments worth $463 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $97.92 |
|---|---|
| AbbVie Inc. | $84.07 |
| Novo Nordisk Inc | $62.72 |
| Amgen Inc. | $54.05 |
| Lilly USA, LLC | $41.32 |
| Radius Health, Inc. | $22.80 |
| Teva Pharmaceuticals USA, Inc. | $21.89 |
| Tolmar, Inc. | $17.14 |
| Food and Beverage | $463 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $366,690 in research payments for these studies, mostly to the institutions running them.
- A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age
ModernaTX, Inc. · Completed · NCT06602024
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.